Acurx Pharmaceuticals announced that the United States Patent and Trademark Office (USPTO) has granted a new US patent, US 12,534,470. This latest patent, which covers DNA Polymerase IIIC inhibitors including compositions?of?matter, methods of use and pharmaceutical compositions, further strengthens Acurx's Intellectual Property (IP) portfolio and represents the most recent addition to its expanding series of granted patents in the US and abroad.

Speaking in this regard, Robert J DeLuccia, Executive Chairman, Acurx, stated, "Achieving this new patent extends our patent estate protection as we further develop our innovative, AI-supported drug discovery platform. We believe Acurx's inventions have the potential to create a transformational shift in the treatment paradigm for serious and potentially life-threatening infections. Recently presented microbiome selectivity data on representative novel compounds from our pre-clinical pipeline provides initial evidence that microbiome selectivity, when compared to the comparator antibiotic, linezolid, may be a class effect."

To date, Acurx has secured four US patents, along with granted patents in Israel, Japan, India and Australia, all of which protect key aspects of the company's ACX?375C programme targeting DNA Polymerase IIIC. Additional country?level patent applications remain under review.

DeLuccia further stated, "While our lead DNA pol IIIC inhibitor, ibezapolstat, is phase III-ready for oral treatment of C difficile infection, and has validated the bacterial target for DNA pol IIIC inhibitors, initial studies of our new pre-clinical compounds show that they are systemically absorbed for potential oral and parenteral use in clinical settings such as Acute Bacterial Skin and Skin-Structure Infections (ABSSSI, including MRSA), Community-Acquired Bacterial Pneumonia (CABP), Hospital and/or Ventilator-Associated Bacterial Pneumonia (HABP/VABP); bacteremia with or without sepsis and/or infectious endocarditis; bone/joint infections, prosthetic joint infections and inhalational anthrax, caused by B anthracis, a Bioterrorism Category A Threat-Level pathogen."